The most recent trading session ended with Ginkgo Bioworks Holdings, Inc. (DNA) standing at $8.09, reflecting a -1.94% shift from the previouse trading day's closing. This change was narrower than the ...

FDA announces plan to end mandatory animal testing of new drugs, replacing it with more effective and human relevant methods.

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a ...

The average of price targets set by Wall Street analysts indicates a potential upside of 41.6% in Ginkgo Bioworks (DNA). While the effectiveness of this highly sought-after metric is questionable, the ...

Ginkgo Bioworks (DNA) announced a new contract with the Advanced Research Projects Agency for Health, or ARPA-H, alongside partners Tritica ...

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) stands against other best ...

Ginkgo Bioworks (DNA) and partners awarded $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems BOSTON ...

This page features the latest news about the Ginkgo Bioworks stock. Ginkgo Bioworks Teams Up with Partners on ARPA-H Project to Stabilize Pharmaceutical Supply Chains - Using Amber Waves of Grain ...